| WDMF | wall-defective microbial forms |
|---|---|
| CIN | 3, CIN III cervical intraepithelial neoplasia, grade 3 (severe dysplasia and carcinoma in situ) |
| DSM-III-R | Diagnostic and Statistical Manual of Mental Disorders [of APA], third edition, revised |
| MS | I, II, III, IV medical student-first, second, third, and fourth year |
| DNA | Deoxyribo-Nucleic Acid |
pseudounipolar bipolar III disorder
transverse facial vein
acute angle
| palpebra III | The semilunar fold formed by the palpebral conjunctiva at the medial angle of the eye, a fold of the conjunctival mucous membrane found in many animals; normally partially hidden in the medial canthus of the eye when at rest, it may be extended to cover part or all of the cornea in a winking-like action to clean the cornea, as in birds. Synonym: membrana nictitans, nictitating membrane, palpebra III, palpebra tertia, third eyelid. Synonym: plica lunata, plica semilunaris of eye, semilunar conjunctival fold. (05 Mar 2000) |
|---|---|
| ramus collateralis arteriarum intercostalium posteriorum III-XI | Branch arising near angle of rib and descending to run along superior border of rib below; distribution: lower half of intercostal spaces 3-11; anastomoses: collateral branches of anterior intercostal arteries. Synonym: ramus collateralis arteriarum intercostalium posteriorum III-XI. (05 Mar 2000) |
| ramus cutaneus medialis rami dorsalis arteriarum intercostalium posteriorum III-XI | Medial cutaneous branch of dorsal branch of posterior intercostal arteries. See: medial cutaneous branch. (05 Mar 2000) |
| ramus dorsalis arteriarum intercostalium posteriorum III-XI | Terminal branch (with ventral branch) of the 3rd through 11th posterior intercostal arteries, distributed to thoracic portion of posterior vertebral column, spinal cord and environs, and back. Synonym: ramus dorsalis arteriarum intercostalium posteriorum III-XI. (05 Mar 2000) |
| malocclusion, angle class III | Malocclusion in which the mandible is anterior to the maxilla as reflected by the first relationship of the first permanent molar (mesioclusion). (12 Dec 1998) |
| virus III of rabbits | An obsolete name for a latent herpesvirus infection of rabbits. Origin: the third strain isolated, used for study (05 Mar 2000) |
| glycogen storage disease type III | <disease> An autosomal recessive metabolic disorder due to deficient expression of amylo-1,6-glucosidase (one part of the glycogen debranching enzyme system). The clinical course of the disease is similar to that of glycogen storage disease type I, but milder. Massive hepatomegaly, which is present in young children, diminishes and occasionally disappears with age. Levels of glycogen with short outer branches are elevated in muscle, liver, and erythrocytes. Six subgroups have been identified, with subgroups type IIIa and type IIIb being the most prevalent. Inheritance: autosomal recessive (12 Dec 1998) |
| grade III astrocytoma | <tumour> Astrocytoma of intermediate grade. See: glioblastoma multiforme. (05 Mar 2000) |
| group III mycobacteria | Mycobacteria that are either colourless or that slowly produce a light yellow pigment when grown in the presence of light. Organisms placed in this group belong to the species Mycobacterium intracellulare. Synonym: nonchromogens. (05 Mar 2000) |
| RNA polymerase III | <enzyme> A DNA-dependent RNA polymerase present in bacterial, plant, and animal cells. It functions in the nucleoplasmic structure where it transcribes DNA into RNA. It has specific requirements for cations and salt and has shown an intermediate sensitivity to alpha-amanitin in comparison to RNA polymerase I and II. Registry number: EC 2.7.7.- (12 Dec 1998) |
| phase III clinical trial | <pharmacology> An advanced stage clinical trial that should conclusively show how well a drug works as compared to other treatments. Phase III trials are large, frequently multi-institution tests. They generally compare the relative value of the new drug compared with the current standard treatment and measure whether a new drug extends survival or otherwise improves the health of patients on treatment (clinical improvement) rather than just provide surrogate marker data. These studies generally last longer and are larger than phase II trials. (31 Dec 1997) |
| class III | All other perennial streams not meeting higher class criteria. (05 Dec 1998) |
| class III antigens | Non-cell membrane molecules that are encoded by the S region of the major histocompatibility complex. These antigens are not involved in determining histocompatibility and include the complement proteins. (05 Mar 2000) |
| class III malocclusion | <dentistry> A Malocclusion where your lower teeth stick out past your upper teeth. This is also called an underbite. (05 Mar 2000) |
| clinical trial, phase III | A pre-planned, usually controlled, clinical study of the safety and efficacy of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques after phase II trials. A large enough group of patients is studied and closely monitored by physicians for adverse response to long-term exposure, over a period of about three years in either the united states or a foreign country. (12 Dec 1998) |